Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results

A 35-yr-old woman is described as having atypical McCune-Albright syndrome, associated with acromegaly and hyperprolactinemia due to pituitary adenoma. The patient did not present sexual precocity, but primary amenorrhea. After transphenoidal adenomectomy, the GH plasma levels returned to normal, wh...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 75; no. 4; p. 1166
Main Authors Cremonini, N, Graziano, E, Chiarini, V, Sforza, A, Zampa, G A
Format Journal Article
LanguageEnglish
Published United States 01.10.1992
Subjects
Acromegaly - blood
Acromegaly - drug therapy
Acromegaly - etiology
Adenoma - complications
Adult
Bromocriptine - therapeutic use
Drug Therapy, Combination
Female
Fibrous Dysplasia, Polyostotic - complications
Growth Hormone - blood
Growth Hormone - drug effects
Humans
Hyperprolactinemia - blood
Hyperprolactinemia - drug therapy
Hyperprolactinemia - etiology
Octreotide - therapeutic use
Pituitary Neoplasms - complications
Online AccessGet more information

Cover

More Information
Summary:A 35-yr-old woman is described as having atypical McCune-Albright syndrome, associated with acromegaly and hyperprolactinemia due to pituitary adenoma. The patient did not present sexual precocity, but primary amenorrhea. After transphenoidal adenomectomy, the GH plasma levels returned to normal, whereas the PRL values decreased; bromocriptine therapy normalized PRL levels and induced ovulatory menses. After 4 uneventful yr the patient developed relapse of active acromegaly that did not recover after a second neurosurgical exploration. Bromocriptine treatment maintained normal PRL levels but did not significantly reduce GH ones; the association with long-acting somatostatin analog SMS 201-995 by continuous sc pump infusion induced definitive control of GH and somatomedin-C secretion. These results suggest an additive inhibitory effect on GH secretion exerted by the two drugs.
ISSN:0021-972X
DOI:10.1210/jc.75.4.1166